$PBAX News
Last published 2y ago
- 2y agoCEROPBAXPhoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business CombinationBusiness WirePhoenix Biotech Acquisition Corp. (NASDAQ:PBAX) ("PBAX") and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic
- 3y agoPBAXCERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell TherapeuticsBusiness WireCERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to enter clinical trials in
- 3y agoPBAXIntrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination AgreementGlobeNewswireSEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech
- 4y agoPBAXIntrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis DisordersGlobeNewswireIntrinsic's pipeline consists of drug candidates based on human milk oligosaccharides (HMOs), which are bioactive small molecules that naturally occur in human milk, with the potential to transform the treatment of
- 5y agoPBAXPBAXUPhoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment OptionGlobeNewswireOakland, CA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the "Company"), a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or si